Tags : ICD Therapeutics

Boehringer Ingelheim (BI) to Acquire ICD Therapeutics for its MacroDel

Shots: Boehringer Ingelheim acquires ICD Therapeutics in all stock transaction, to utilize ICD’s MacroDel biologics-delivery platform to develop oncology therapies for intracellular delivery of macromolecules (peptides and proteins) The focus of the acquisition is to enhance Boehringer’s oncology portfolio with the development of therapies for intracellular targets for tumor cell types ICD’s MacroDel technology is […]Read More